Timeline secures CHF 56 million to propel its pioneering role in longevity and healthy aging
24 January 2024
Timeline, a Vaud-based biotech leader in healthy aging and longevity, has announced a pivotal CHF 56 million investment in its Series D financing round.
Founded in 2007 by Chris Rinsch and Patrick Aebischer as a spin-off from the EPFL, Timeline (formerly Amazentis) has been on the cutting edge of developing innovative solutions for healthy aging. The company’s core technology, Mitopure, has been the cornerstone of this progress.
With over 15 years of research backing, Mitopure is clinically proven to target a key cellular longevity pathway, focusing on recycling and renewing mitochondria, the cell’s powerhouse. This technology is central to supporting muscle strength, cognition, immune resilience, and skin vitality, among other aging aspects. The CHF 56 million investment reflects the robust confidence of investors in Timeline’s proprietary technology and its potential to revolutionize the longevity and health span sector.
L’Oréal, through its Deputy CEO Barbara Lavernos, highlighted the intersection of longevity with beauty, stating: “Longevity is a new definition of beauty… Our investment in Timeline is exciting for its potential to transpose key hallmarks of longevity onto skin health and beauty.”
Expanding into a leading consumer health brand in the longevity sector
Nestlé, a long-standing investor since 2019, remains impressed with Timeline’s potential. Anna Mohl, CEO of Nestlé Health Science, noted the exponential potential of Mitopure technology in nutrition and aging. The joining of L’Oréal as an investor and strategic partner is expected to propel Mitopure technology to new heights and broaden its applications. The funds from this investment will be channeled towards expanding Timeline into a leading consumer health brand in the longevity sector, focusing on science, product categories, and markets across food, beauty, and health sectors.